Junyu Zhai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junyu Zhai has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jun Li
Department of Cardiac Surgery, Zhongshan Hospital Fudan University, China
2 shared publications Beibei He
Department of Cardiac Surgery, Zhongshan Hospital Fudan University
1 shared publication- Ben Huang
Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
1 shared publication Chenxing Huang
Departments of Cardiology (Y. Zou, Z.L., J.J., Q.L., J.M.J.W., K.J., X.R., Y. Zhang, C.H., Y.X., H.G., J. Lin, J.G., Y.D.), Shanghai Institute of Cardiovascular Diseases
1 shared publicationChunsheng Wang
Department of Cardiac Surgery, Zhongshan Hospital Fudan University
1 shared publication- Chunsheng Wang
Department of Cardiac Surgery and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1970128
Transcriptomic screening and in vitro validation suggest PENK involvement in mitochondrial quality-control dysregulation in diabetes-associated myocardial injury
Background: Mitochondrial dysfunction and dysregulated mitochondrial quality control (MQC) contribute to diabetes-associated myocardial injury. However, the potential involvement of proenkephalin (PENK) in cardiomyocyte injury and mitochondrial dysfunction under hyperglycemic conditions remains poorly understood. This study aimed to identify MQC-associated candidate genes and investigate the functional relevance of PENK in high-glucose-induced cardiomyocyte injury. Methods: GSE4745 was used as the discovery cohort for differential expression analysis, MQC-related pathway enrichment, and weighted gene co-expression network analysis (WGCNA). Candidate genes were prioritized using an integrated discovery-based scoring approach and further evaluated in three supportive GEO cohorts (GSE5606, GSE6880, and GSE197999). PENK expression and function were investigated in high-glucose-treated AC16 cardiomyocytes. Two independent PENK-targeting siRNAs were used to assess cell viability, apoptosis-associated protein expression, mitochondrial superoxide-related fluorescence, and mitochondrial membrane potential. MQC-associated protein expression was also examined by Western blotting. Results: Transcriptomic analysis identified 192 differentially expressed genes, including 58 MQC-related genes, and revealed alterations in fatty-acid oxidation, mitochondrial protein import, and mitophagy/autophagy-associated transcriptional programs. PENK emerged as a high-ranking candidate and exhibited increased expression in diabetic myocardial samples, with concordant expression changes across the supportive cohorts. High-glucose exposure increased PENK expression and impaired AC16 cell viability and mitochondrial function. PENK knockdown significantly improved cell viability, reduced cleaved caspase-3 expression and mitochondrial superoxide-related fluorescence, and increased the JC-1 red/green fluorescence ratio. These changes were accompanied by reduced PINK1, Parkin, and DRP1 protein abundance and increased MFN2 expression. Importantly, an independent si-PENK #2 experiment reproduced the improvements in cellular injury and mitochondrial phenotypes observed with si-PENK #1. Conclusions: This study identifies PENK as an MQC-associated candidate involved in high-glucose-induced cardiomyocyte injury. Consistent findings from two independent PENK-targeting siRNAs indicate that PENK suppression attenuates cellular injury and improves mitochondrial functional phenotypes under hyperglycemic stress. These findings provide experimental evidence supporting the potential relevance of PENK to mitochondrial dysfunction in diabetes-associated myocardial injury.
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1970128
Open AccessTranscriptomic screening and in vitro validation suggest PENK involvement in mitochondrial quality-control dysregulation in diabetes-associated myocardial injury
Background: Mitochondrial dysfunction and dysregulated mitochondrial quality control (MQC) contribute to diabetes-associated myocardial injury. However, the potential involvement of proenkephalin (PENK) in cardiomyocyte injury and mitochondrial dysfunction under hyperglycemic conditions remains poorly understood. This study aimed to identify MQC-associated candidate genes and investigate the functional relevance of PENK in high-glucose-induced cardiomyocyte injury. Methods: GSE4745 was used as the discovery cohort for differential expression analysis, MQC-related pathway enrichment, and weighted gene co-expression network analysis (WGCNA). Candidate genes were prioritized using an integrated discovery-based scoring approach and further evaluated in three supportive GEO cohorts (GSE5606, GSE6880, and GSE197999). PENK expression and function were investigated in high-glucose-treated AC16 cardiomyocytes. Two independent PENK-targeting siRNAs were used to assess cell viability, apoptosis-associated protein expression, mitochondrial superoxide-related fluorescence, and mitochondrial membrane potential. MQC-associated protein expression was also examined by Western blotting. Results: Transcriptomic analysis identified 192 differentially expressed genes, including 58 MQC-related genes, and revealed alterations in fatty-acid oxidation, mitochondrial protein import, and mitophagy/autophagy-associated transcriptional programs. PENK emerged as a high-ranking candidate and exhibited increased expression in diabetic myocardial samples, with concordant expression changes across the supportive cohorts. High-glucose exposure increased PENK expression and impaired AC16 cell viability and mitochondrial function. PENK knockdown significantly improved cell viability, reduced cleaved caspase-3 expression and mitochondrial superoxide-related fluorescence, and increased the JC-1 red/green fluorescence ratio. These changes were accompanied by reduced PINK1, Parkin, and DRP1 protein abundance and increased MFN2 expression. Importantly, an independent si-PENK #2 experiment reproduced the improvements in cellular injury and mitochondrial phenotypes observed with si-PENK #1. Conclusions: This study identifies PENK as an MQC-associated candidate involved in high-glucose-induced cardiomyocyte injury. Consistent findings from two independent PENK-targeting siRNAs indicate that PENK suppression attenuates cellular injury and improves mitochondrial functional phenotypes under hyperglycemic stress. These findings provide experimental evidence supporting the potential relevance of PENK to mitochondrial dysfunction in diabetes-associated myocardial injury.
- Open Access
- 30 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2218
Integrated Analysis of Serotonin-Related Biomarkers in Thoracic Aortic Aneurysm Based on Machine Learning and Single-Cell Sequencing Data
Background: Serotonin, as an important neurotransmitter and signaling molecule, can affect thoracic aortic aneurysm (TAA) by regulating vascular cell proliferation, angiogenesis, and immune status. This research aimed to conduct a comprehensive analysis to pinpoint serotonin-related biomarkers in TAA and to elucidate their potential molecular mechanisms. Methods: Biomarkers were selected and validated through differential expression analysis, weighted gene co-expression network analysis (WGCNA), machine learning algorithms, and expression verification. Moreover, the constructed nomogram, enrichment analysis, immune infiltration analysis, and compound prediction validated the regulatory roles of the biomarkers in TAA. The single-cell dataset was analyzed to determine key cells and perform pseudo-time analysis. Simulated knockout of biomarkers was performed to determine their underlying functions and related pathways. Finally, reverse transcription quantitative PCR (RT-qPCR) was employed to confirm the expression levels of the biomarkers. Results: Overall, two biomarkers (CD300A and CLU) were determined to be associated with serotonin in TAA. The nomogram showed good performance in predicting TAA risk. These biomarkers were significantly enriched in the hematopoietic cell lineage and natural killer (NK) cell mediated cytotoxicity. Biomarker expression was significantly correlated with the infiltration proportions of M2 macrophages and neutrophils. The biomarkers were stably bound to tetrachlorodibenzodioxin and bisphenol A. Moreover, pseudo-time analysis demonstrated a notable correlation between biomarker expression and the differentiation status of monocytes/macrophages/dendritic cells (MonoMac/DC). Genes perturbed by knockout were enriched in the pyrimidine metabolism and RIG-I-like receptor signaling pathway. Finally, RT-qPCR validated that CLU was downregulated and CD300A was upregulated in the TAA group. Conclusions: Biomarkers (CD300A and CLU) associated with serotonin in TAA were identified, with their expression trends validated by RT-qPCR. This work provides novel bioinformatic insights, and direct functional experiments are required to support future therapeutic development for TAA.
- 30 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2218
Open AccessIntegrated Analysis of Serotonin-Related Biomarkers in Thoracic Aortic Aneurysm Based on Machine Learning and Single-Cell Sequencing Data
Background: Serotonin, as an important neurotransmitter and signaling molecule, can affect thoracic aortic aneurysm (TAA) by regulating vascular cell proliferation, angiogenesis, and immune status. This research aimed to conduct a comprehensive analysis to pinpoint serotonin-related biomarkers in TAA and to elucidate their potential molecular mechanisms. Methods: Biomarkers were selected and validated through differential expression analysis, weighted gene co-expression network analysis (WGCNA), machine learning algorithms, and expression verification. Moreover, the constructed nomogram, enrichment analysis, immune infiltration analysis, and compound prediction validated the regulatory roles of the biomarkers in TAA. The single-cell dataset was analyzed to determine key cells and perform pseudo-time analysis. Simulated knockout of biomarkers was performed to determine their underlying functions and related pathways. Finally, reverse transcription quantitative PCR (RT-qPCR) was employed to confirm the expression levels of the biomarkers. Results: Overall, two biomarkers (CD300A and CLU) were determined to be associated with serotonin in TAA. The nomogram showed good performance in predicting TAA risk. These biomarkers were significantly enriched in the hematopoietic cell lineage and natural killer (NK) cell mediated cytotoxicity. Biomarker expression was significantly correlated with the infiltration proportions of M2 macrophages and neutrophils. The biomarkers were stably bound to tetrachlorodibenzodioxin and bisphenol A. Moreover, pseudo-time analysis demonstrated a notable correlation between biomarker expression and the differentiation status of monocytes/macrophages/dendritic cells (MonoMac/DC). Genes perturbed by knockout were enriched in the pyrimidine metabolism and RIG-I-like receptor signaling pathway. Finally, RT-qPCR validated that CLU was downregulated and CD300A was upregulated in the TAA group. Conclusions: Biomarkers (CD300A and CLU) associated with serotonin in TAA were identified, with their expression trends validated by RT-qPCR. This work provides novel bioinformatic insights, and direct functional experiments are required to support future therapeutic development for TAA.
- Open Access
- 24 June 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (25) , 1780-1796
Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2–Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear. METHODS: Whole-exome sequencing identified a novel DSC2 sequence variation causing autosomal recessive ARVC in a Chinese family with consanguineous marriage. Mouse models with Dsc2 sequence variation knock-in and constitutive knock-out were generated and analyzed using echocardiography and histology. Transcriptomic and biochemical analyses were conducted to explore ARVC mechanisms. Dsc2 mRNA delivered by intracardiac or transcoronary injection was assessed as a treatment for ARVC in Dsc2 knock-out mice. In addition, effects of Dsc2 mRNA were examined in a transverse aortic constriction mouse model with noninherited right ventricular systolic dysfunction. RESULTS: Dsc2 -deficient mice exhibited right ventricular dilation and dysfunction, mimicking human disease. Transcriptomic analysis identified Myl7 as the most downregulated gene in the right ventricles of Dsc2 -deficient mice, and its restoration by adeno-associated virus 9 rescued heart function. Dsc2 mRNA delivery, with or without lipid nanoparticle encapsulation, normalized heart size and function in Dsc2 -deficient mice. Reduced DSC2 and MLC2a expression was also noted in patients with noninherited dilated cardiomyopathy and in mice with transverse aortic constriction. A single dose of mRNA provided therapeutic effects lasting 2 to 3 months before declining. CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by DSC2 loss of function, supported by human and mouse data. Loss of Myl7 contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. Dsc2 mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.
- 24 June 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (25) , 1780-1796
Open AccessModified mRNA Treatment Restores Cardiac Function in Desmocollin-2–Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear. METHODS: Whole-exome sequencing identified a novel DSC2 sequence variation causing autosomal recessive ARVC in a Chinese family with consanguineous marriage. Mouse models with Dsc2 sequence variation knock-in and constitutive knock-out were generated and analyzed using echocardiography and histology. Transcriptomic and biochemical analyses were conducted to explore ARVC mechanisms. Dsc2 mRNA delivered by intracardiac or transcoronary injection was assessed as a treatment for ARVC in Dsc2 knock-out mice. In addition, effects of Dsc2 mRNA were examined in a transverse aortic constriction mouse model with noninherited right ventricular systolic dysfunction. RESULTS: Dsc2 -deficient mice exhibited right ventricular dilation and dysfunction, mimicking human disease. Transcriptomic analysis identified Myl7 as the most downregulated gene in the right ventricles of Dsc2 -deficient mice, and its restoration by adeno-associated virus 9 rescued heart function. Dsc2 mRNA delivery, with or without lipid nanoparticle encapsulation, normalized heart size and function in Dsc2 -deficient mice. Reduced DSC2 and MLC2a expression was also noted in patients with noninherited dilated cardiomyopathy and in mice with transverse aortic constriction. A single dose of mRNA provided therapeutic effects lasting 2 to 3 months before declining. CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by DSC2 loss of function, supported by human and mouse data. Loss of Myl7 contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. Dsc2 mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.